Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells

US11098053B2 · kind B2 · utility

Assignees

• The Administrators of the Tulane Educational Fund · US
• Xavier University of Louisiana · US
• The United States of America, as represented by the Secretary of Agriculture · US

Inventors

• Amy Strong · New Orleans, US
• Stephen M. Boue · New Orleans, US
• Matthew E. Burow · New Orleans, US
• Bruce Alan Bunnell · Mandeville, US
• Quan Jiang · New Orleans, US
• Shilong Zheng · New Orleans, US
• Guangdi Wang · New Orleans, US

Key dates

• Filing date: Apr 4, 2014
• Grant date: Aug 24, 2021
• Expiry date: Apr 4, 2034

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61L2430/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are daidzein analogs having the formula (I). Also disclosed are compositions, include a disclosed daidzein analogs, methods of preventing or treating bone disease or bone injury and/or stimulating bone growth, in a subject that include administering to the subject an effective amount of disclosed daidzein analog. Disclosed are isolated mesenchymal stem cell that has been altered by treatment a disclosed daidzein analog, daidzein, glycinol, glyceollin I, or glyceollin II, to increase the osteogenic potential of the mesenchymal stem cells.